1. Home
  2. PODD vs VTRS Comparison

PODD vs VTRS Comparison

Compare PODD & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$215.93

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.50

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PODD
VTRS
Founded
2000
1961
Country
United States
United States
Employees
N/A
30000
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
17.2B
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
PODD
VTRS
Price
$215.93
$13.50
Analyst Decision
Strong Buy
Buy
Analyst Count
20
4
Target Price
$357.65
$13.50
AVG Volume (30 Days)
839.7K
9.5M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
3.59%
EPS Growth
N/A
N/A
EPS
3.48
N/A
Revenue
$2,708,100,000.00
$14,299,900,000.00
Revenue This Year
$24.33
$4.45
Revenue Next Year
$19.33
$1.79
P/E Ratio
$64.99
N/A
Revenue Growth
30.73
N/A
52 Week Low
$216.49
$6.85
52 Week High
$354.88
$16.47

Technical Indicators

Market Signals
Indicator
PODD
VTRS
Relative Strength Index (RSI) 29.20 40.04
Support Level N/A $12.92
Resistance Level $299.75 $16.38
Average True Range (ATR) 7.61 0.40
MACD -0.52 -0.11
Stochastic Oscillator 1.66 30.38

Price Performance

Historical Comparison
PODD
VTRS

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: